专利检索 ap:("The United States of America, as Represented by The Secretary, Department of Health AND Human Services") AND inv:"MALHOTRA, Sanjay, V." 第 1 页

1.

发明公开
NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER 有权
标题翻译：核受体调节剂和它们用于治疗和预防癌症

公开(公告)号：EP2721003A1

公开(公告)日：2014-04-23

申请号：EP12800764.8

申请日：2012-06-15

申请人： The United States of America, as Represented by The Secretary, Department of Health and Human Services

发明人： NECKERS, Jane, B. , KIM, Yeong, Sang , LEE, Sunmin , KUMAR, Vineet , MALHOTRA, Sanjay, V.

IPC分类号： C07C255/50 , C07C317/44 , C07C49/796 , C07C49/235 , A61K9/10 , A61K31/12 , A61P35/00

CPC分类号： C07C49/796 , A61K31/12 , A61K31/275 , A61K45/06 , C07C49/80 , C07C49/813 , C07C49/84 , C07C205/45 , C07C255/56 , A61K2300/00

摘要： Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R
1 to R
5 and X
1 to X
5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

2.

发明授权
NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER 有权
标题翻译：核受体调节剂及其治疗和预防癌症的应用

公开(公告)号：EP2721003B1

公开(公告)日：2018-01-03

申请号：EP12800764.8

申请日：2012-06-15

申请人： The United States of America, as Represented by The Secretary, Department of Health and Human Services

发明人： NECKERS, Jane, B. , KIM, Yeong, Sang , LEE, Sunmin , KUMAR, Vineet , MALHOTRA, Sanjay, V.

IPC分类号： C07C255/50 , C07C317/44 , C07C49/796 , C07C49/235 , A61K9/10 , A61K31/12 , A61P35/00

CPC分类号： C07C49/796 , A61K31/12 , A61K31/275 , A61K45/06 , C07C49/80 , C07C49/813 , C07C49/84 , C07C205/45 , C07C255/56 , A61K2300/00

摘要： Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R 1 to R 5 and X 1 to X 5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.